Fibromyalgia severity scores showed modest seasonal variations, with higher widespread pain reported during autumn vs summer.

The FDA has approved Osvyrti (denosumab-desu), a biosimilar to Prolia (denosumab), and Jubereq (denosumab-desu), a biosimilar to Xgeva (denosumab).

Most countries involved in FDA drug-approval trials do not receive timely market authorization for the studied drugs.

The global incidence of RA increased between 1990 and 2021, with rates estimated to continue rising through 2040.

A self-administered, at-home hypnosis intervention may help reduce the number of hot flashes experienced by postmenopausal women.

Nonartricular pain — particularly widespread NAP — was linked to worse physical, emotional, and social well-being among adults with early RA.

The ACR issued a 2025 guideline for the treatment of SLE that addressed treatment and management of specific organ system ...

There was a decline in confirmed cases of child maltreatment in the US from 2012 through 2023, though no change was seen in referrals.

An analysis of kidney biopsies before and after obinutuzumab treatment of lupus nephritis showed histologic remission or near remission in a greater proportion of patients than had complete renal ...

Deep learning-based automated osteoporosis screening may be able to identify patients with low BMD using existing medical images.